Literature DB >> 17653908

Association of NAT2 gene substitution mutation T341C with increased risk for head and neck cancer in Tunisia.

Sonia Gara1, Monia Abdennebi, Samia Chatti, Slim Touati, Abderrahmen Ladgham, Fethi Guemira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17653908     DOI： 10.1080/02841860601096833

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  6 in total

1.  Association of CYP1A1 and CYP2D6 gene polymorphisms with head and neck cancer in Tunisian patients.

Authors:  Rim Khlifi; Amine Chakroun; Amel Hamza-Chaffai; Ahmed Rebai
Journal:  Mol Biol Rep       Date:  2014-01-22       Impact factor: 2.316

2.  Inter-ethnic differences in genetic polymorphisms of xenobiotic-metabolizing enzymes (CYP1A1, CYP2D6, NAT1 and NAT2) in healthy populations: correlation with the functional in silico prediction.

Authors:  Rim Khlifi; Ghada Ben Salah; Amine Chakroun; Amel Hamza-Chaffai; Ahmed Rebai
Journal:  Mol Biol Rep       Date:  2014-06-17       Impact factor: 2.316

3.  N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case-control studies.

Authors:  Liang Zhang; Zhaolan Xiang; Rui Hao; Ru Li; Yi Zhu
Journal:  Tumour Biol       Date:  2013-12-13

4.  Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis.

Authors:  Youyang Zheng; Yong Li; Yaoshu Teng; Zhen Zhang; Xiaolin Cao
Journal:  Oncol Lett       Date:  2011-11-24       Impact factor: 2.967

Review 5.  Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers.

Authors:  Rim Khlifi; Olfa Messaoud; Ahmed Rebai; Amel Hamza-Chaffai
Journal:  Biomed Res Int       Date:  2013-09-16       Impact factor: 3.411

Review 6.  A Review of Cancer Genetics and Genomics Studies in Africa.

Authors:  Solomon O Rotimi; Oluwakemi A Rotimi; Bodour Salhia
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 5.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.